The World’s First Multi-Modality AI-Powered Worklist is Now Available to EU Hospitals via Zebra Medical Vision
Zebra Medical Vision (https://www.zebra-med.com/), the deep learning imaging analytics company, announces it’s been granted CE certification to two Zebra-Med products that accelerate clinical review and diagnosis of acute conditions in medical imaging. The AI technology can flag time-critical cases such as pneumothorax in chest x-rays and brain bleeds in CT scans. The technology reduces the time it takes radiologists and ER staff to spot acute conditions by 80%! This speed, in turn, improves the quality and timeliness of treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190228005326/en/
(Graphic: Zebra Medical Vision)
Zebra-med’s acute insights line of products is part of a growing list of solutions now offered to health providers and governments. The Zebra-Med imaging analytics engine connects to any PACS system and analyzes relevant scans with corresponding algorithms. Once an acute condition is detected, a standard HL7 message alerts the hospitals’ various systems, such as the radiology department or ER department worklists. Each hospital can customize the way the alert is presented in the worklist, either with color coding or priority ranking. The technology can be deployed on-premise or via the cloud, and neither method compromisess the radiology core workflow, originally acquired images, or risks breaching protected health information data laws.
Pneumothorax, the presence of gas within the pleural space between the lung and the chest wall, remains a globally important health problem with considerable associated morbidity and healthcare costs. Without prompt management, pneumothorax can lead to total lung collapse and other potentially fatal complications. It can be spontaneous or can be caused by underlying lung disease, trauma, or complications from biopsies or surgical procedures. With an estimated incidence rate of 18-28 cases per 100,000 population, there are between 130,000 - 207,000 cases of pneumothorax in Europe every year. Misdiagnosis or late-diagnosis of Pneumothorax impacts around 74,000 americans per year.
Brain bleed is even more prevalent and accounts for approximately 8-15% of all strokes in western countries. It impacts almost 3.6 million Americans each year. Strokes or traumatic brain injury occur every 9 seconds, and diagnostic brain scans can cost $150,000 per patient. Brain bleed is a devastating disease, with a high 30-day mortality rate that ranges from 35% to 52%. It is estimated that about 50% of this mortality occurs within the first 24 hours, emphasizing the importance of early detection and effective treatment in the Emergency Department.
“In a clinical validation study we performed, Zebra-med’s acute CXR pneumothorax and CT brain bleed products demonstrated a promising potential to substantially reduce turn around time and increase the radiologist's confidence in making these diagnoses,” said Dr. Terence Matalon, MD, FACR, FSIR Chairman, Diagnostic Radiology at Albert Einstein Medical Center. "Seeing the software in action emphasized key aspects AI solutions must address in order impact our field: high accuracy, speed, seamless integration to our workflow, and the ability to work on multi modalities - both X-ray and CT."
“Our acute-findings line of products emphasizes the Zebra Medical Vision team’s dedication to providing AI solutions to the majority of radiology departments worldwide who are reading and reporting more than just one modality,” says Eyal Gura, Zebra-Med’s CEO and Co-Founder. “We are thrilled to make this solution available today to hospitals across Europe that work with the many PACS and worklist systems that already integrate Zebra-Med’s software.”
Zebra-Med works with some of the world’s leading health providers, which together operate over 100 hospitals. Last year, Zebra-MEd received 8 CE marks for various algorithms and 510(k) FDA clearance for its Coronary Calcium Scoring algorithm, expanding company’s footprint in the US. In addition to the recently announced Israel Innovation Authority grants, Zebra-Med has raised over $50 million from a range of investors over three funding rounds.
*The acute-findings solutions are available for sale in the European Union, 510(k)-pending. Not available for sale in the USA.
Visit Zebra-Med’s blog.
About Zebra Medical Vision
Zebra Medical Vision uses deep learning to create and provide next generation products and services to the healthcare industry. Its Imaging Analytics Platform allows healthcare institutions to identify patients at risk of disease, and offer improved, preventative treatment pathways to improve patient care. Headquartered in Kibbutz Shefayim Israel, Zebra was founded in 2014 by Co-Founders Eyal Toledano, Eyal Gura, and Elad Benjamin and funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia, J&J, and Dolby Ventures. For more information, visit www.zebra-med.com.
Blonde 2.0 for Zebra Medical Vision
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 12:00:00 CEST | Pressemelding
Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan
Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 10:13:00 CEST | Pressemelding
Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste
WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 09:38:00 CEST | Pressemelding
The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici
Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 08:00:00 CEST | Pressemelding
Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an
CNT Among SAP’s "Best of the Best"17.5.2019 08:00:00 CEST | Pressemelding
Since 2005, SAP is honoring the best of the best SAP projects yearly in Europe, Middle East and Africa. In 2018, 280 customers from 15 markets submitted their regional Gold Award-winning projects. CNT Management Consulting from Vienna won Bronze twice – together with its customers HOERBIGER and TANNPAPIER – a happy day for CNT’s CEO Andreas Doerner. "We are now on the podium for the second time with two projects – thanks to the trust of our customers." The SAP Quality Awards EMEA were presented at an exceptionally festive ceremony in Heidelberg Castle (Baden-Wuerttemberg), and only twelve SAP customers were able to take home the most wanted trophies that were presented by SAP Presidents Brian Duffy (EMEA North) and Hartmut Thomsen (Middle and Eastern Europe). The jury evaluated the projects according to the ten SAP quality principles and the question of whether the respective project could fulfill the expectations of its clients. HOERBIGER - Category Business Transformation Headquarter
EVER Pharma acquires Amneal Deutschland GmbH and extends its commercial presence in Europe17.5.2019 07:25:00 CEST | Pressemelding
EVER Pharma Holding Ges.m.b.H (Austria) announced today that it has completed the acquisition of Amneal Deutschland GmbH, a subsidiary of Amneal Pharmaceuticals that operates the company's commercial operations in Germany. Amneal Deutschland already distributes several EVER Pharma products in Germany and is a strongly established player in the German hospital market. The acquired entity will be rebranded to EVER Pharma GmbH. “This acquisition represents another milestone in the expansion of EVER Pharma’s commercial footprint in Europe. With this new operation, EVER Pharma extends its portfolio in Germany and establishes a solid platform for the growth of its portfolio and pipeline” commented Georges Kahwati, General Manager of EVER Pharma. “We are pleased to establish another EVER affiliate in one of the key European markets in line with our strategy of establishing our own business presence in core markets.” added Julia Hillebrand, Managing Director and Owner. About EVER Pharma: EVER